Clinical trials: SARS
COVID-19 Virus Infection
Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)
This is a randomized, double blind, placebo parallel-controlled phase III clinical trial to evaluate the efficacy, immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in Argentine healthy population aged…
- Trial name
- NCT04560881
- Testing
- Inactivated SARS-CoV-2 vaccine (Vero cell)
- Where
- 4 sites in Argentina
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Laboratorio Elea Phoenix S.A.
SARS-CoV, SARS-CoV-2
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in adults.
- Trial name
- NCT05938075
- Testing
- VXCO-100, COVID-19 mRNA vaccine
- Where
- 2 sites in South Africa
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Covid-19
Correlation of Antibody Response to COVID-19 Vaccination in Pregnant Woman and Transplacental Passage Into Cord Blood.
The goal of this study is to study the correlation of maternal and cord blood level of Anti SAR-CoV.
- Trial name
- NCT06259656
- Testing
- COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)
- Where
- Thailand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vachira Phuket Hospital
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, COVID-19 Pandemic
- Trial name
- NCT05364268
- Testing
- Diagnostic Test: Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 514 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
COVID-19, SARS-CoV-2
Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19
The purpose of this study is to to evaluate the safety and immune response of COVI-VAC given as a single booster dose in healthy adults previously vaccinated against COVID-19 with an authorised mRNA or adenovirus-vectored…
- Trial name
- NCT05233826
- Testing
- COVI-VAC
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
COVID-19 Vaccines
A Study of COVID-19 Vaccine(s) in Children and Adults
The purpose of this study is to learn about the safety and effects of updated COVID-19 vaccines (called BNT162b2) in participants 5 Through 64 Years of Age with risk factors for Severe COVID-19, and Participants 65 Years of Age…
- Trial name
- NCT07798648
- Testing
- BNT162b2
- Where
- 14 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Prevention
Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray
The purpose of this study is to test the safety of multiple doses of a Q-GRFT nasal spray in healthy volunteers. This Q-GRFT nasal spray is "investigational and not approved by the FDA for general use" and is being developed to…
- Trial name
- NCT05437029
- Testing
- Q-Griffithsin 3.0, Q-Griffithsin 6.0
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kenneth Palmer
Fertility Issues, Vaccine Adverse Reaction
COVID-19 Vaccine and Ovarian Reserve
As Israel is the first country to widely vaccinate its population using the mRNA vaccine against COVID-19, evaluating its influence on ovarian reserve is essential .
- Trial name
- NCT04748172
- Testing
- SARS-CoV-2 virus vaccines, AMH sampling, anti Covid-19 antibody levels (Serology)
- Where
- Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
COVID-19
Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]
PRIBIVAC will assess a heterologous prime-boost-boost strategy in comparison with a homologous regimen in order to compare short and long-term immunogenicity of different COVID-19 vaccine combinations against the ancestral…
- Trial name
- PRIBIVAC (NCT05142319)
- Testing
- Homologous mRNA booster vaccine, Heterologous mRNA booster vaccine, COVAXIN
- Where
- Singapore
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
COVID-19
Inhaled Ivermectin and COVID-19
Coronavirus disease-19 is global healthcare crisis. Till May 20, 2020, there were approximately 4,789,205 cases and 318,789 related mortalities were identified globally.
- Trial name
- CCOVID-19 (NCT04681053)
- Testing
- Ivermectin Powder
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Covid19
Detection of SARS-CoV-2 in Nasopharyngeal Swabs by Using Multi-Spectral Screening System
The aim of this research is to use the Multi-Spectral method to measure the biomolecular fingerprint of the virus directly instead of the virus's RNA (RT-PCR) or the body's immune response (antibody) measurement methods to…
- Trial name
- NCT04860895
- Testing
- AP-23
- Where
- Turkey (Türkiye)
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Fable Biyoteknoloji San ve Tic A.S
Covid19, SARS-CoV Infection
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2…
- Conditions
- Covid19, SARS-CoV Infection, Corona Virus Infection
- Trial name
- NCT04668339
- Testing
- ARCT-021 single dose priming, ARCT-021 two lower dose priming, ARCT-021 two higher dose priming
- Where
- 15 sites in United States, Singapore
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Healthy Participants
A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone.
- Trial name
- NCT05886777
- Testing
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF
- Where
- 37 sites in United States
- Volunteers
- 1,142 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2 Infection, SARS-CoV-2 Vaccination
Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination
Accuracy validation of the designed and manufactured ELISpot-based in vitro diagnostic 'Corona-T-test' for detection of SARS-CoV-2-specific T cells.
- Trial name
- NCT05165719
- Testing
- Corona-T-test
- Where
- Russia
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- National Research Center for Hematology, Russia
COVID-19, Sars-CoV-2 Infection
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
The objective of this study is to evaluate the immunogenicity and safety of SCTV01E in participants aged ≥18 years and previously fully immunized with mRNA COVID-19 vaccine.
- Trial name
- NCT05238441
- Testing
- SCTV01E, Comirnaty
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
A Phase I clinical study to evaluate the safety, tolerability, and immunogenicity of SARS-CoV-2 variant (Omicron) mRNA vaccine which is used to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2…
- Trial name
- NCT05433194
- Testing
- ABO1009-DP
- Where
- United Arab Emirates
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Vaccine Reaction, Vaccine Adverse Reaction
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
A Phase III, Observer-blind, randomized, active-controlled prospective intervention study
- Trial name
- NCT05546502
- Testing
- SARS-CoV-2 Protein Subunit Recombinant Vaccine, Active Comparator
- Where
- 10 sites in Indonesia
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Coronavirus
A Study of a Candidate COVID-19 Vaccine (COV003)
A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine.
- Trial name
- NCT04536051
- Testing
- ChAdOx1 nCoV-19 single dose + paracetamol, MenACWY single dose + paracetamol, ChAdOx1 nCoV-19 two dose + paracetamol
- Where
- 6 sites in Brazil
- Volunteers
- 10,300 people, healthy volunteers welcome
- Sponsor
- University of Oxford
PASC Post Acute Sequelae of COVID-19
Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)
This study uses total-body [¹⁸F]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID.
- Trial name
- NCT07076862
- Testing
- A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only), B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
COVID-19
Saliva as Source of Detection for SARS-CoV-2
Background: Nasopharyngeal (NP) swabbing is being used to test for SARS-CoV-2 infection. For this, a swab is inserted deep into the back of the nose to collect a sample. It can cause discomfort for most people.
- Trial name
- NCT04424446
- Where
- 2 sites in United States
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.